The Pink Sheet | Combination Therapies: Incentives Needed To Encourage Labeling Across Products

Senators Bernie Sanders (I-VT) and Roger Marshall (R-KS) released a new draft health bill, the “Bipartisan Primary Care and Health Workforce Act,” and CMS announced Medicare beneficiary copays for 34 prescription drugs may be lower between October and December 2023.

Marc Scheineson comments on what the Food and Drug Administration’s emergency use authorization update for COVID-19 drug Paxlovid could mean for other therapies.

Alston & Bird has expanded its health care and life sciences regulatory and compliance capabilities with the addition of counsel Alexandra Marzelli, former associate chief counsel at the U.S. Food and Drug Administration (FDA). Based in the firm’s Washington, D.C. office, Marzelli joins Alston & Bird’s Health Care and FDA/Food, Drug & Device Groups, where she will advise clients on the FDA’s complex approval process and regulatory compliance for prescription and over-the-counter drugs, biologics, medical devices, food ingredients, and other products regulated by the agency.

Marc Scheineson comments on President Biden’s nomination of Robert for a second term as commissioner of the U.S. Food and Drug Administration.

Marc Scheineson is quoted on the appointment of Janet Woodcock as acting commissioner of the U.S. Food and Drug Administration.